EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Progression-Free Survival with PARP Inhibitors According to Clinical Risk in Patients with Ovarian Cancer: An Indirect Comparison Using Reconstructed Data

Lorenzo Gasperoni iD, Luna Del Bono, Alberto Farolfi, Andrea Messori, Vera Damuzzo

Oncology Research · 2026 · 34 (7) · 1-10

DOI: 10.32604/or.2026.077700 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Oncology Research, 2026. Verfasst von Lorenzo Gasperoni und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Department, USL Toscana Centro, Prato, Italy. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsHumansFemaleProgression-Free SurvivalAntineoplastic Combined Chemotherapy ProtocolsRandomized Controlled Trials as TopicPhthalazinesPiperazinesBevacizumabMiddle AgedPiperidinesIndazoles

Stichwörter der Autor:innen

IPDfromKMadvanced ovarian cancerindirect comparisonpoly (ADP-ribose) polymerase (PARP) inhibitors

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsolaparibPhthalazinesPiperazinesniraparibBevacizumabPiperidinesIndazoles

Autor:innen und Institutionen

  • Pharmaceutical Department, USL Toscana Centro, Prato, Italy.
  • Department of Pharmacy, School of Specialization in Hospital Pharmacy, University of Pisa, Pisa, Italy.
  • Medical Oncology, Breast & GYN Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
  • HTA Unit, Regional Health Service, Firenze, Italy.
  • Italian Society of Clinical Pharmacy and Therapeutics (SIFaCT), Torino, Italy.
  • Hospital Pharmacy Department, Azienda Ulss 2 Marca Trevigiana, Treviso, Italy.

ORCID-Profile: Lorenzo Gasperoni

Zitieren

APA

Gasperoni, L., Del Bono, L., Farolfi, A., Messori, A., & Damuzzo, V. (2026). Progression-Free Survival with PARP Inhibitors According to Clinical Risk in Patients with Ovarian Cancer: An Indirect Comparison Using Reconstructed Data. Oncology Research, 34(7), 1-10. https://doi.org/10.32604/or.2026.077700

Vancouver

Gasperoni L, Del Bono L, Farolfi A, Messori A, Damuzzo V. Progression-Free Survival with PARP Inhibitors According to Clinical Risk in Patients with Ovarian Cancer: An Indirect Comparison Using Reconstructed Data. Oncology Research. 2026;34(7):1-10. doi:10.32604/or.2026.077700

BibTeX
@article{Gasperoni2026,
  author = {Gasperoni, Lorenzo and Del Bono, Luna and Farolfi, Alberto and Messori, Andrea and Damuzzo, Vera},
  title = {Progression-Free Survival with PARP Inhibitors According to Clinical Risk in Patients with Ovarian Cancer: An Indirect Comparison Using Reconstructed Data},
  journal = {Oncology Research},
  year = {2026},
  volume = {34},
  number = {7},
  pages = {1--10},
  doi = {10.32604/or.2026.077700}
}
Kostenlos starten →